Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852871 | 0.92 | MAPT (0.36) | MAPTTHRBKMT2ACYP2D6TP53 | |
| SCHEMBL26734850 | 0.85 | MAPT (0.40) | MAPTTHRBKMT2ACNR2HTT | |
| SCHEMBL24035966 | 0.85 | MAPT (0.38) | MAPTTHRBKMT2ACNR2HTT | |
| SCHEMBL24853071 | 0.79 | MAPT (0.36) | MAPTTHRBKMT2ATP53 | |
| SCHEMBL26735192 | 0.79 | IRAK4 (0.33) | MAPTTHRBCNR2ACSS2CNR1 | |
| SCHEMBL24035963 | 0.79 | CNR2 (0.31) | MAPTTHRBCNR2TP53CNR1 | |
| SCHEMBL26735719 | 0.78 | CYP2D6 (0.41) | MAPTTHRBKMT2ACYP2D6CNR2 | |
| SCHEMBL24035241 | 0.78 | CYP2D6 (0.43) | MAPTCYP2D6CNR2TP53CNR1 | |
| SCHEMBL24035888 | 0.77 | MAPT (0.38) | MAPTTHRBKMT2AHTTTP53 | |
| SCHEMBL24852874 | 0.77 | MAPT (0.37) | MAPTTHRBKMT2AHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | MAPT 4180/4885THRB 2152/4885KMT2A 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.